2020 BIO Investor Forum Buzz of BIO Finalist
Excision BioTherapeutics develops curative therapies for viral infectious diseases. The company’s technology platform is based on in vivo CRISPR-based gene editing and is the first and only to remove HIV genomes from living animals to achieve functional cures (Dash et al, Nat Comm 2019). The company's pipeline includes programs for HIV, Herpes Virus, JC Virus/PML, and Hepatitis B. Excision is nearing clinical-stage: the company plans to submit its IND for EBT-101 for HIV in 2020 and begin Phase 1/2 trials in 2021. The foundational technology was developed at Kamel Khalili’s Neurovirology Lab at Temple University and Jennifer Doudna’s biochemistry gene editing lab at UC Berkeley. Excision has exclusive licenses to technology from Temple, Stanford, and UC Berkeley in addition to multiple internal patent families. The company is private and located in San Francisco.
Excision BioTherapeutics develops curative therapies for viral infectious diseases. The company’s technology platform is based on in vivo CRISPR-based gene editing and is the first and only to remove HIV genomes from living animals to achieve functional cures (Dash et al, Nat Comm 2019). The company's pipeline includes programs for HIV, Herpes Virus, JC Virus/PML, and Hepatitis B. Excision is nearing clinical-stage: the company plans to submit its IND for EBT-101 for HIV in 2020 and begin Phase 1/2 trials in 2021. The foundational technology was developed at Kamel Khalili’s Neurovirology Lab at Temple University and Jennifer Doudna’s biochemistry gene editing lab at UC Berkeley. Excision has exclusive licenses to technology from Temple, Stanford, and UC Berkeley in addition to multiple internal patent families. The company is private and located in San Francisco.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2015
Main Therapeutic Focus:
Gene/Cell Therapy
Lead Product in Development:
EBT-101: Functional Cure for HIV
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
